Gynecology · Uterine Adenomyoma

Treatment Options and Managing Symptoms

At a Glance

Treatment for uterine adenomyoma is individualized based on bleeding, pain, lesion size and location, atypical features, and fertility goals. Medicines usually control symptoms, while surgery may remove the lesion or uterus; atypical polypoid adenomyoma requires close follow-up.

Treatment for a uterine adenomyoma is rarely “one-size-fits-all.” Because these growths are benign (non-cancerous), the primary goal of treatment is usually to improve your quality of life by managing symptoms like heavy bleeding and pain ^[1]. However, if you have been diagnosed with the atypical (APA) variant, your treatment plan will also focus on reducing the risk of the lesion returning or progressing ^[2].

Medical Management: Controlling Symptoms

It is important to understand that medical treatments generally manage symptoms in selected patients, but they do not reliably eliminate the adenomyoma itself ^[3]. Much of the evidence for these therapies is extrapolated from diffuse adenomyosis rather than localized focal lesions.

Nonhormonal Care: This includes clinician-directed iron replacement for anemia, as well as NSAIDs or tranexamic acid to manage pain and heavy bleeding ^[1].
Progestins and Dienogest: These hormones help thin the uterine lining to reduce bleeding and pain, but they can cause irregular spotting ^[3]^[4].
Levonorgestrel-releasing IUD (LNG-IUS): Often known by brand names like Mirena, this device is placed in the uterus to deliver hormones directly to the lining ^[5]. It must be removed before attempting pregnancy.
GnRH Agonists and Antagonists: These medications (such as Lupron or linzagolix) temporarily put the body into a “menopause-like” state ^[6].
- Side Effects: These can cause hot flashes and a decrease in bone mineral density ^[7]. Availability, approved indications, duration, and the need for “add-back” therapy vary by jurisdiction and patient ^[6].

Surgical Options

Surgery may be recommended if medical treatments fail, if the growth is very large, or if you have an atypical polypoid adenomyoma (APA).

Uterus-Sparing Surgery

For those who wish to preserve their fertility or keep their uterus, surgeons can often remove just the adenomyoma:

Hysteroscopic Resection: If the adenomyoma is polypoid (on a stalk) or sits just under the uterine lining, it can often be removed using a small camera ^[8]^[2]. This may sometimes require staged procedures.
Adenomyomectomy: This involves removing the localized nodule from the uterine muscle ^[9]. While this can significantly reduce pain and bleeding, it carries risks of bleeding, adhesions, uterine scarring, and pregnancy-related risks such as uterine rupture or abnormal placentation depending on the depth ^[10].

Definitive Treatment: Hysterectomy

A hysterectomy (removal of the uterus) is a definitive treatment for diffuse adenomyosis and eliminates the uterus-related risk in APA ^[5].

It is often considered when patients have completed childbearing or when atypical cells continue to return ^[11]^[12].
It ends the ability to carry a pregnancy, but it does not automatically mean the ovaries are removed, nor does it guarantee immediate menopause. Ask your specialist about the expected recovery ^[2].

Investigational and Emerging Alternatives

Percutaneous Microwave Ablation (PMWA) is a newer, minimally invasive option where a needle-like probe uses heat to destroy the abnormal tissue ^[13].

Results: While early data suggests it can improve symptoms within 3 to 12 months in some populations, evidence specifically for uterine adenomyoma/APA is limited ^[13]^[14].
A Note of Caution: It is not standard in many settings, and its effects on future pregnancy and later pathology assessment are uncertain ^[15]. It should not be used as a substitute for complete excision and pathology when atypia is suspected ^[16].

Special Considerations for APA

Management of APA depends heavily on confirmation by an expert pathologist, exclusion of concurrent EIN/carcinoma, completeness of the lesion’s removal, age, symptoms, and fertility goals ^[2]. Because APAs have a risk of recurring (estimated in some retrospective cohorts at 29–35%) or progressing (estimated at 10–16%), personalized follow-up is necessary ^[2]^[17]. Your specialist will help you navigate your specific risks rather than treating these figures as universal.

Common questions in this guide

What is the usual treatment for a uterine adenomyoma?

Treatment depends on the adenomyoma’s size, location, symptoms, whether it has atypical features, and your plans for pregnancy. Medicines usually reduce heavy bleeding and pain but do not reliably remove the growth. Surgery may be considered when symptoms persist, the growth is large, or atypical polypoid adenomyoma is present.

Can medication get rid of a uterine adenomyoma?

Medicines generally manage symptoms rather than eliminate a uterine adenomyoma. Nonhormonal options can help with pain, heavy bleeding, or anemia, while hormonal treatments may reduce bleeding and pain. Your clinician can help choose an option based on side effects, health history, and fertility plans.

Can a uterine adenomyoma be removed without a hysterectomy?

Often, yes. A polypoid or superficial adenomyoma may be removed through the vagina and cervix with hysteroscopic resection, while a deeper nodule may require adenomyomectomy, which removes the growth from the uterine muscle. These uterus-sparing procedures can affect future pregnancy and may cause bleeding, adhesions, or scarring.

When is hysterectomy considered for uterine adenomyoma?

Hysterectomy may be considered when symptoms continue despite medical treatment, when childbearing is complete, or when atypical cells keep returning. It removes the uterus and ends the ability to carry a pregnancy, but the ovaries are not automatically removed and menopause does not necessarily happen immediately.

How is atypical polypoid adenomyoma treated and monitored?

Management of atypical polypoid adenomyoma depends on expert pathology review, whether the lesion was completely removed, your age and symptoms, and your fertility goals. Options may include uterus-sparing removal with follow-up hysteroscopies or hysterectomy, depending on individual risk. Follow-up is important because the lesion can recur or progress.

Is microwave ablation an option for uterine adenomyoma?

Percutaneous microwave ablation is an emerging treatment that uses heat to destroy abnormal tissue, but evidence for uterine adenomyoma and atypical polypoid adenomyoma is limited. It is not standard in many settings, and its effects on future pregnancy and later pathology assessment are uncertain. It should not replace complete removal and pathology when atypia is suspected.

What side effects can GnRH medicines cause?

GnRH agonists and antagonists can cause hot flashes and other menopause-like symptoms, and they may reduce bone mineral density. The approved uses, treatment duration, and need for add-back therapy vary by person and location. Ask your clinician how bone health will be monitored and whether add-back therapy is appropriate.

Get notified when new evidence is published on adenomyoma of uterine corpus.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (17)

1
Guideline No. 437: Diagnosis and Management of Adenomyosis.
Dason ES, Maxim M, Sanders A, et al.
Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC 2023; (45(6)):417-429.e1 doi:10.1016/j.jogc.2023.04.008.
PMID: 37244746
2
Management of women with atypical polypoid adenomyoma of the uterus: A quantitative systematic review.
Raffone A, Travaglino A, Saccone G, et al.
Acta obstetricia et gynecologica Scandinavica 2019; (98(7)):842-855 doi:10.1111/aogs.13553.
PMID: 30714089
3
Compare the Efficacy of Dienogest and the Levonorgestrel Intrauterine System in Women with Adenomyosis.
Guo W, Lin Y, Hu S, Shen Y
Clinical therapeutics 2023; (45(10)):973-976 doi:10.1016/j.clinthera.2023.07.019.
PMID: 37599165
4
A cohort study of the efficacy of the dienogest and the gonadotropin-releasing hormone agonist in women with adenomyosis and dysmenorrhea.
Ji M, Yuan M, Jiao X, et al.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2022; (38(2)):164-169 doi:10.1080/09513590.2021.2000961.
PMID: 34749585
5
The Present and the Future of Medical Therapies for Adenomyosis: A Narrative Review.
Moawad G, Youssef Y, Fruscalzo A, et al.
Journal of clinical medicine 2023; (12(19)) doi:10.3390/jcm12196130.
PMID: 37834773
6
Role of oral gonadotropin-releasing hormone antagonists in the management of uterine adenomyosis: a narrative review.
Donnez J, Donnez O, Taylor HS, et al.
Reproduction & fertility 2026; (7(3)) doi:10.1530/RAF-26-0075.
PMID: 42599074
7
Uterine Adenomyosis Treated by Linzagolix, an Oral Gonadotropin-Releasing Hormone Receptor Antagonist: A Pilot Study with a New 'Hit Hard First and then Maintain' Regimen of Administration.
Donnez J, Donnez O, Tourniaire J, et al.
Journal of clinical medicine 2021; (10(24)) doi:10.3390/jcm10245794.
PMID: 34945090
8
Polypoid Adenomyoma of the Uterus.
Sajjad N, Iqbal H, Khandwala K, Afzal S
Cureus 2019; (11(2)):e4044 doi:10.7759/cureus.4044.
PMID: 31016072
9
Conservative surgery of uterine adenomyosis via laparoscopic versus laparotomic approach in a single institution.
Kwack JY, Im KS, Kwon YS
The journal of obstetrics and gynaecology research 2018; (44(7)):1268-1273 doi:10.1111/jog.13658.
PMID: 29845687
10
Comparisons of the efficacy and recurrence of adenomyomectomy for severe uterine diffuse adenomyosis via laparotomy versus laparoscopy: a long-term result in a single institution.
Zhu L, Chen S, Che X, et al.
Journal of pain research 2019; (12()):1917-1924 doi:10.2147/JPR.S205561.
PMID: 31303783
11
Conservative surgical treatment of adenomyosis to improve fertility: Controversial values, indications, complications, and pregnancy outcomes.
Tsui KH, Lee FK, Seow KM, et al.
Taiwanese journal of obstetrics & gynecology 2015; (54(6)):635-40.
PMID: 26700977
12
Pregnant outcomes of atypical polypoid adenomyoma treated with progestin therapy.
Chen Q, Lu W, Lu B
The journal of obstetrics and gynaecology research 2018; (44(2)):323-330 doi:10.1111/jog.13527.
PMID: 29121416
13
Value of contrast-enhanced ultrasonography in microwave ablation treatment of symptomatic focal uterine adenomyosis.
Li XL, Li JX, Yu SY, et al.
Ultrasonography (Seoul, Korea) 2024; (43(1)):68-77 doi:10.14366/usg.23145.
PMID: 38109892
14
Use of contrast-enhanced ultrasound in evaluating the efficacy and application value of microwave ablation for adenomyosis.
Xu C, Tang Y, Zhao Y, et al.
Journal of cancer research and therapeutics 2020; (16(2)):365-371 doi:10.4103/jcrt.JCRT_769_18.
PMID: 32474525
15
Percutaneous cryoablation of symptomatic uterine adenomyomas: Initial experience.
Marcelin C, Brun JL, Caprais J, et al.
Journal of gynecology obstetrics and human reproduction 2024; (53(3)):102727 doi:10.1016/j.jogoh.2024.102727.
PMID: 38237806
16
Comparison of Clinical and Reproductive Outcomes between Adenomyomectomy and Myomectomy.
Hlinecka K, Mara M, Boudova B, et al.
Journal of minimally invasive gynecology 2022; (29(3)):392-400 doi:10.1016/j.jmig.2021.10.005.
PMID: 34670164
17
Clinical presentation and management of atypical polypoid adenomyomas: Systematic review of the literature.
Mikos T, Tsolakidis D, Grimbizis GF
European journal of obstetrics, gynecology, and reproductive biology 2019; (236()):14-21 doi:10.1016/j.ejogrb.2019.02.027.
PMID: 30875539

This page is for informational purposes only and does not constitute medical advice. A gynecologist or specialist can help you weigh symptom control, fertility goals, and follow-up for your specific uterine adenomyoma.